Takeda Takhzyro
Children Ages 2 To <12 Experienced 94.8% Fewer Hereditary Angioedema (Hae) Attacks During Treatment With Takhzyro Over The 52-Week Treatment Period Compared To BaselineLate-Breaking Flash Talk Presentation Of Phase 3 Data Highlights Positive, Clinically Meaningful Results In Children <6 Years, Where No Long-Term Prophylaxis Treatment (Ltp) Is Currently ApprovedResults Are Consistent With The Favorable Efficacy And Safety Profile Of Takhzyro Observed In Adult And Adolescent Patients In Earlier StudiesGlobal Regulatory Filings To Begin In Fiscal Year 2022Takeda Today Announced Late-Breaking Data From The Phase 3 Spring Study (Nct04070326) Presented At The European Academy Of Allergy And Clinical Immunology (Eaaci) Hybrid Congress 2022, Demonstrating Positive Results Of Takhzyro
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
